The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

Garinis, Angela C.; Cross, Campbell P.; Srikanth, Priya; Carroll, Kelly; Feeney, M. Patrick; Keefe, Douglas H.; Hunter, Lisa L.; Putterman, Daniel; Cohen, David; Gold, Jeffrey A.; Steyger, Peter S.

doi:10.1016/j.jcf.2017.01.006

Cited by 87 publications

(73 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nonetheless, these drugs can induce acute dose-dependent kidney failure (nephrotoxicity), and permanent hearing loss (cochleotoxicity; defined here as hearing loss in the conventional frequency range, i.e., <8 kHz) and/or balance disorders (vestibulotoxicity). Aminoglycoside-induced vestibulotoxicity and/or cochleotoxicity occurs in as many as 20% of patients who received these drugs intravenously for multiple days (Ariano et al, 2008 ; Al-Malky et al, 2015 ; Garinis et al, 2017a ). Hearing loss delays speech acquisition, education and psychosocial development, reducing employability, income and tax revenues (Jones and White, 1990 ; Järvelin et al, 1997 ; Mehl and Thomson, 1998 ; Naramura et al, 1999 ; Tambs, 2004 ), with a socioeconomic burden >$1,393,000 in 2015 dollars over the life-time of each pre-lingually deafened child (Mohr et al, 2000 ).…”

Section: Aminoglycoside Antibioticsmentioning

confidence: 99%

Aminoglycoside-Induced Cochleotoxicity: A Review

Jiang

Karasawa

Steyger

2017

Front. Cell. Neurosci.

Self Cite

220

165

View full text Add to dashboard Cite

Aminoglycoside antibiotics are used as prophylaxis, or urgent treatment, for many life-threatening bacterial infections, including tuberculosis, sepsis, respiratory infections in cystic fibrosis, complex urinary tract infections and endocarditis. Although aminoglycosides are clinically-essential antibiotics, the mechanisms underlying their selective toxicity to the kidney and inner ear continue to be unraveled despite more than 70 years of investigation. The following mechanisms each contribute to aminoglycoside-induced toxicity after systemic administration: (1) drug trafficking across endothelial and epithelial barrier layers; (2) sensory cell uptake of these drugs; and (3) disruption of intracellular physiological pathways. Specific factors can increase the risk of drug-induced toxicity, including sustained exposure to higher levels of ambient sound, and selected therapeutic agents such as loop diuretics and glycopeptides. Serious bacterial infections (requiring life-saving aminoglycoside treatment) induce systemic inflammatory responses that also potentiate the degree of ototoxicity and permanent hearing loss. We discuss prospective clinical strategies to protect auditory and vestibular function from aminoglycoside ototoxicity, including reduced cochlear or sensory cell uptake of aminoglycosides, and otoprotection by ameliorating intracellular cytotoxicity.

show abstract

Section: Aminoglycoside Antibioticsmentioning

confidence: 99%

Aminoglycoside-Induced Cochleotoxicity: A Review

Jiang

Karasawa

Steyger

2017

Front. Cell. Neurosci.

Self Cite

220

165

View full text Add to dashboard Cite

show abstract

“…Aminoglycoside-induced ototoxicity can manifest as vestibulotoxicity (balance disorder) and/or cochleotoxicity (tinnitus and/or hearing loss) with intravenous aminoglycoside administration for multiple days, espe-cially if multiple courses of treatment are administered (24,(31)(32)(33). Ototoxicity prevalence varies from 2 to 25% for cochleotoxicity and 1 to 10% for vestibulotoxicity (24,(31)(32)(33). Ototoxicity may be permanent, occurs in a dosedependent manner, and is correlated with aminoglycoside blood concentration and duration of therapy; furthermore, patients may be genetically predisposed to ototoxicity via specific mitochondrial or nuclear genome mutations (33).…”

Section: Associated Toxicitiesmentioning

confidence: 99%

Aminoglycoside Revival: Review of a Historically Important Class of Antimicrobials Undergoing Rejuvenation

Serio¹,

Keepers²,

Andrews³

et al. 2018

EcoSal Plus

118

View full text Add to dashboard Cite

Aminoglycosides are cidal inhibitors of bacterial protein synthesis that have been utilized for the treatment of serious bacterial infections for almost 80 years. There have been approximately 15 members of this class approved worldwide for the treatment of a variety of infections, many serious and life threatening. While aminoglycoside use declined due to the introduction of other antibiotic classes such as cephalosporins, fluoroquinolones, and carbapenems, there has been a resurgence of interest in the class as multidrug-resistant pathogens have spread globally. Furthermore, aminoglycosides are recommended as part of combination therapy for empiric treatment of certain difficult-totreat infections. The development of semisynthetic aminoglycosides designed to overcome common aminoglycoside resistance mechanisms, and the shift to once-daily dosing, has spurred renewed interest in the class. Plazomicin is the first new aminoglycoside to be approved by the FDA in nearly 40 years, marking the successful start of a new campaign to rejuvenate the class. AMINOGLYCOSIDE HISTORY Aminoglycoside antimicrobials were first discovered in the 1940s and originally isolated from actinomycetes. Streptomycin, isolated from Streptomyces griseus, was the first aminoglycoside introduced into clinical practice for the treatment of tuberculosis (1, 2). Selman Waksman (the first to coin the term "antibiotic") won the Nobel Prize in 1952 for the discovery of streptomycin, along with Albert Schatz, who was eventually recognized as a codiscoverer. Since then, a number of aminoglycosides have been discovered as products from the Streptomyces group ("mycin" aminoglycosides, e.g., neomycin, kanamycin, tobramycin) or Micromonospora group ("micin" aminoglycosides, e.g., gentamicin, sisomicin) species, or developed through chemical modifications using existing aminoglycoside scaffolds (e.g., amikacin, netilmicin, arbekacin, plazomicin). Plazomicin is an aminoglycoside that was engineered to overcome aminoglycoside-modifying enzymes (AMEs), the most common aminoglycoside resistance mechanism in Enterobacteriaceae, and is the first aminoglycoside to be approved by the FDA (June 2018) since the approval of amikacin in 1981, marking the beginning of a class rejuvenation.

show abstract

“…The effects of aging on the auditory system are considered the leading cause of adult-onset hearing loss [5]. The association between hearing loss and genetic mutations [6], noise exposure [7], use of ototoxic drugs in treatment [8,9], and chronic diseases such as hypertension and diabetes [10,11] has also been demonstrated in existent studies.…”

Section: Introductionmentioning

confidence: 99%

The association between reduced kidney function and hearing loss: a cross-sectional study

et al. 2020

View full text Add to dashboard Cite

Background: The relationship between kidney function and hearing loss has long been recognized, but evidence of this association mostly comes from small observational studies or other populations. The aim of this study is to explore the association between reduced kidney function and hearing loss in a large population-based study among the middle-aged and elderly Chinese. Methods: Data collected from the Chinese Health and Retirement Longitudinal Study (CHARLS) in 2015 were used for analysis. A cross-sectional study was conducted among 12,508 participants aged 45 years and older. Hearing loss, the outcome of this study, was defined according to interviewees' responses to three survey questions related to hearing in the CHARLS. Estimated glomerular filtration rate (eGFR) was employed to assess kidney function, and participants were classified into three categories based on eGFR: ≥90, 60-89 and < 60 mL/min/1.73 m 2. Multivariable logistic regression was employed to adjust for potential confounders, including demographics, health-related behaviors, and cardiovascular risk factors. Results: The overall prevalence of self-reported hearing loss in the study population was 23.6%. Compared with participants with eGFR ≥90 mL/min/1.73 m 2 , participants with eGFR of 60-89 mL/min/1.73 m 2 (odds ratio [OR]: 1.11, 95% confidence interval [CI]: 1.00-1.23) and eGFR < 60 mL/min/1.73 m 2 (OR: 1.25, 95% CI: 1.04-1.49) showed increased risk of hearing loss after adjusting for potential confounders. Conclusions: Reduced kidney function is independently associated with hearing loss. Testing for hearing should be included in the integrated management of patients with chronic kidney disease.

show abstract

The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis

Cited by 87 publications

References 39 publications

Aminoglycoside-Induced Cochleotoxicity: A Review

Aminoglycoside-Induced Cochleotoxicity: A Review

Aminoglycoside Revival: Review of a Historically Important Class of Antimicrobials Undergoing Rejuvenation

The association between reduced kidney function and hearing loss: a cross-sectional study

Contact Info

Product

Resources

About